A US focused cannabis operator provided its shareholders with a progress report on its development in the northern Las Vegas area.

Marapharm Ventures (CSE:MDM,OTCQX:MRPHF) issued an update on Thursday (June 14) regarding on the final inspection for its cultivation facilities in North Las Vegas in order to obtain “certificates of occupancy.”

The company is waiting to obtain the critical certificates by the city of North Las Vegas, after a successful inspection from the Public Works Department and an upcoming approval from the North Las Vegas Fire Department.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

Linda Sampson, CEO of Marapharm, said the facilities of the company will be able to produce “triple organic” strains soon to debut in their dispensaries in Las Vegas.

The company also shared with investors three of its medical certificates for production and cultivation were renewed for 2018-2019, while its three recreational ones are currently in the same renewed process.

Marapharm also announced the official ordering of the early development for a planned phase 2 construction of a 65,000 square feet three-story cultivation facility. According to a market projection by Statista, the current forecast for the estimated sales of marijuana in Nevada reach US$814 million in 2025. For 2019 the research firm projected sales of cannabis reaching US$433 million.

Earlier in the year, the Associated Press reported medical and recreational sales for the month of February brought in close to US$6 million in taxes. Chief state economist Bill Anderson told the AP sales in the state have surpassed projections every month.

Following a strong initial strong reaction from the market, after the trading session ended on Thursday, Marapharm’s shares increased 1.23 percent to reach a price of C$0.41.

Marapharm raises capital in Canada through the Canadian Securities Exchange (CSE), a stock market that has enjoyed a rush of cannabis listings since it welcomes US operations despite the country’s legal status of the drug.

Barrington Miller told the Investing News Network (INN) the CSE made a conscious decision not to block US companies with cannabis assets in the country even if they were unlicensed. Now as the momentum appears to be increasing for changes in the legality of cannabis and businesses in the industry for the US, the CSE seems poised to benefit from the newfound interest in the stocks operating the US market.

Don’t forget to follow us @INN_Cannabis for real-time news updates! Stay tuned to our cannabis channel for more stories from Lift.

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less